OptiNose reports pivotal phase III results for migraine treatment developed using bi-directional breath powered technology
AVP-825 is an investigational drug-device combination product developed by OptiNose which uses OptiNose’s patented Bi-Directional Breath Powered technology to deliver a low dose of sumatriptan powder into the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.